

Infected Fractures

Title: A Phase 2a Randomized, Single-Blind, Placebo-Controlled, 24-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Osteosynthesis Sites.

Purpose: To evaluate the safety and tolerability of single escalating doses of locally administered MBN-101 or placebo as adjunct to standard of care antimicrobial and surgical therapy

Eligibility: Patients with infected fracture sites.

PI: [Janet D. Conway, M.D.](#)

Phase: IIA